502 related articles for article (PubMed ID: 30738364)
21. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.
Zhang T; Zhu J; George DJ; Armstrong AJ
Expert Opin Pharmacother; 2015 Mar; 16(4):473-85. PubMed ID: 25534660
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis.
Perletti G; Monti E; Marras E; Cleves A; Magri V; Trinchieri A; Rennie PS
Arch Ital Urol Androl; 2015 Jul; 87(2):121-9. PubMed ID: 26150028
[TBL] [Abstract][Full Text] [Related]
23. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.
Caffo O; De Giorgi U; Fratino L; Alesini D; Zagonel V; Facchini G; Gasparro D; Ortega C; Tucci M; Verderame F; Campadelli E; Lo Re G; Procopio G; Sabbatini R; Donini M; Morelli F; Sartori D; Zucali P; Carrozza F; D'Angelo A; Vicario G; Massari F; Santini D; Sava T; Messina C; Fornarini G; La Torre L; Ricotta R; Aieta M; Mucciarini C; Zustovich F; Macrini S; Burgio SL; Santarossa S; D'Aniello C; Basso U; Tarasconi S; Cortesi E; Buttigliero C; Ruatta F; Veccia A; Conteduca V; Maines F; Galligioni E
Eur Urol; 2015 Jul; 68(1):147-53. PubMed ID: 25457020
[TBL] [Abstract][Full Text] [Related]
24. Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.
Basch E; Loblaw DA; Oliver TK; Carducci M; Chen RC; Frame JN; Garrels K; Hotte S; Kattan MW; Raghavan D; Saad F; Taplin ME; Walker-Dilks C; Williams J; Winquist E; Bennett CL; Wootton T; Rumble RB; Dusetzina SB; Virgo KS
J Clin Oncol; 2014 Oct; 32(30):3436-48. PubMed ID: 25199761
[TBL] [Abstract][Full Text] [Related]
25. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients.
Efstathiou E; Titus M; Wen S; Troncoso P; Hoang A; Corn P; Prokhorova I; Araujo J; Dmuchowski C; Melhem-Bertrandt A; Patil S; Logothetis CJ
Eur Urol Oncol; 2020 Feb; 3(1):119-127. PubMed ID: 31412017
[TBL] [Abstract][Full Text] [Related]
26. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
[TBL] [Abstract][Full Text] [Related]
27. Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Bui CN; O'Day K; Flanders S; Oestreicher N; Francis P; Posta L; Popelar B; Tang H; Balk M
J Manag Care Spec Pharm; 2016 Feb; 22(2):163-70. PubMed ID: 27015255
[TBL] [Abstract][Full Text] [Related]
28. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
[TBL] [Abstract][Full Text] [Related]
29. Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide.
Modena A; Ciccarese C; Fantinel E; Bimbatti D; Tortora G; Massari F
Expert Rev Anticancer Ther; 2015; 15(9):1037-48. PubMed ID: 26134919
[TBL] [Abstract][Full Text] [Related]
30. Current approaches to incorporation of radium-223 in clinical practice.
Parker C; Heidenreich A; Nilsson S; Shore N
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):37-47. PubMed ID: 29298991
[TBL] [Abstract][Full Text] [Related]
31. Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience.
Chang LW; Hung SC; Wang SS; Li JR; Yang CK; Chen CS; Ho HC; Cheng CL; Ou YC; Chiu KY
Anticancer Res; 2019 Jul; 39(7):3901-3908. PubMed ID: 31262919
[TBL] [Abstract][Full Text] [Related]
32. Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer.
Markowski MC; Pienta KJ
Asian J Androl; 2015; 17(6):936-8; discussion 938. PubMed ID: 25865849
[TBL] [Abstract][Full Text] [Related]
33. New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?
Wilson L; Tang J; Zhong L; Balani G; Gipson G; Xiang P; Yu D; Srinivas S
J Oncol Pharm Pract; 2014 Dec; 20(6):417-25. PubMed ID: 24243919
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer.
Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
Clin Genitourin Cancer; 2017 Dec; 15(6):e1073-e1080. PubMed ID: 28826931
[TBL] [Abstract][Full Text] [Related]
35. Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review.
Cursano MC; Iuliani M; Casadei C; Stellato M; Tonini G; Paganelli G; Santini D; De Giorgi U
Crit Rev Oncol Hematol; 2020 Feb; 146():102864. PubMed ID: 31986318
[TBL] [Abstract][Full Text] [Related]
36. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
[TBL] [Abstract][Full Text] [Related]
37. Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer.
To SQ; Kwan EM; Fettke HC; Mant A; Docanto MM; Martelotto L; Bukczynska P; Ng N; Graham LK; Parente P; Pezaro C; Mahon K; Horvath L; Todenhöfer T; Azad AA
Eur Urol; 2018 Jun; 73(6):818-821. PubMed ID: 29398263
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.
Kobayashi K; Okuno N; Arai G; Nakatsu H; Maniwa A; Kamiya N; Satoh T; Kikukawa H; Nasu Y; Uemura H; Nakashima T; Mikami K; Iinuma M; Tanabe K; Furukawa J; Kobayashi H
Jpn J Clin Oncol; 2021 Apr; 51(4):544-551. PubMed ID: 33324967
[TBL] [Abstract][Full Text] [Related]
39. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
Fizazi K; Kramer G; Eymard JC; Sternberg CN; de Bono J; Castellano D; Tombal B; Wülfing C; Liontos M; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Oudard S; Facchini G; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; Bensfia S; de Wit R
Lancet Oncol; 2020 Nov; 21(11):1513-1525. PubMed ID: 32926841
[TBL] [Abstract][Full Text] [Related]
40. Current therapeutic options in metastatic castration-resistant prostate cancer.
Ingrosso G; Detti B; Scartoni D; Lancia A; Giacomelli I; Baki M; Carta G; Livi L; Santoni R
Semin Oncol; 2018 Oct; 45(5-6):303-315. PubMed ID: 30446166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
